Aluvia is a so-called "second-line" drug that would treat the growing number of Thai people who have developed a resistance to "first-line" drug therapies.
Abbott spokeswoman Jennifer Smoter said a compulsory license issued by Thailand to allow generic drugs was unnecessary because Abbott was offering Aluvia in Thailand at a reduced price of $1,000 per patient per year.
Abbott's introduction of the Aluvia tablet in South Africa is part of its five-point global strategy to expand access to HIV treatments around the world by:
Aluvia is indicated for the treatment of HIV-1 infected adults and children above the age of 2 years.
tabs (LPV/r) refrigerated must be swallowed whole Kaletra[R] Oral Crushing the tabs reduces the Aluvia
[R] solution absorption of the drugs should be Kaletra Solution and Capsules: refrigerated administer with food.
Abbott has invested in sufficient manufacturing capacity to meet the anticipated global demand for the Aluvia
tablets and plans to register the lower-strength Aluvia
tablet in 150 countries - broader registration than any other pediatric HIV medicine.
In January, the government of Thailand issued a compulsory license for the manufacture and import of a generic version of the drug; the move prompted Abbott to withdraw all new drugs, including Aluvia
, a heat-stable tablet formulation of Kaletra, from the official governmental approval and registration process in Thailand.
We applaud Abbott today for its offer to significantly reduce the price and increase the availability of Kaletra and Aluvia
in Thailand and other low and lower-middle-income countries, a price that is even less than what the Thai government had been seeking," said Michael Weinstein, AIDS Healthcare Foundation's President.
Despite Abbott's Recent Offer of Price Cut on Key AIDS Drug for Thailand & Elsewhere, US' Largest HIV/AIDS Healthcare, Prevention and Education Provider Blasts Drug Giant for 'Quid Pro Quo' Offer to Slash Price on Aluvia
Only If Thailand Pulls Compulsory License
Despite Kudos for Recent Offers of Price Cuts on Kaletra and Aluvia
in Thailand and Other Lower Middle-income Countries, Nation's Largest Pension System to Query Abbott About Drug Blacklist in Thailand
Abbott's price reduction remains contingent on the Government of Thailand halting the issue of compulsory licenses for Aluvia
LOS ANGELES, April 23 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the US' largest HIV/AIDS healthcare, prevention and education provider, which operates free AIDS treatment clinics in the US, Africa, Latin America/Caribbean and Asia, today chastised US drug giant, Abbott Laboratories for its 'quid pro quo' offer earlier today to the Government of Thailand to lower its price for Abbott's key AIDS drug, Aluvia
(a heat-stable tablet version of Kaletra) to approximately USD$800 per patient per year -- an offer contingent upon Abbott's demand that Thailand immediately halt issuing compulsory licenses for the generic manufacture of this lifesaving drug.